Incannex Announces Positive Topline Results from Phase 2

Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8...

Related Keywords

Melbourne ,Victoria ,Australia ,Monash ,South Australia ,United States ,Joel Latham ,Paul Liknaitzky ,Laine Yonker ,Nasdaq ,Edison Group ,Clinical Psychedelic Lab At Monash University ,Incannex Healthcare Inc ,Drug Administration ,Investigational New Drug ,Clinical Psychedelic Lab ,Monash University ,About Generalised Anxiety ,Anxiety Disorder ,Incannex Board ,Securities Litigation Reform Act ,Executive Officer ,Relations Contact ,Existing Registered Treatments ,